Profile
Sector:
HealthcareCountry:
United StatesIPO:
13 October 2017Website:
http://www.optinose.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:53:49 GMTDividend
Analysts recommendations
Institutional Ownership
OPTN Latest News
OptiNose, Inc. (NASDAQ: OPTN) will be holding its Q1 2024 Results Conference Call on May 15, 2024 at 10:00 AM ET. Company representatives include Jonathan Neely, VP of IR & Business Development, and Dr. Ramy Mahmoud, CEO. Conference call participants include analysts from Lake Street Capital Markets, Piper Sandler, Jefferies, and H.C. Wainwright. The operator begins the call by thanking participants for joining.
Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in patients cared for by ear, nose, and throat (ENT) and allergy specialists, revealed today that its management team will be giving a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
OptiNose (OPTN) reported a quarterly loss of $0.12 per share, slightly higher than the expected loss of $0.10 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.17 per share reported in the same quarter last year.
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.
OptiNose (OPTN) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.23 per share a year ago.
On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023. OptiNose's preliminary net revenue for the second quarter of 2023 was $19.5 million, up 65.3% from the previous quarter and down 5.4% from the first quarter of 2022. On May 4, 2023, the company announced that the FDA had accepted a supplemental new drug application seeking approval for Xhance as a treatment for chronic sinusitis.
What type of business is OptiNose?
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
What sector is OptiNose in?
OptiNose is in the Healthcare sector
What industry is OptiNose in?
OptiNose is in the Drug Manufacturers - Specialty & Generic industry
What country is OptiNose from?
OptiNose is headquartered in United States
When did OptiNose go public?
OptiNose initial public offering (IPO) was on 13 October 2017
What is OptiNose website?
https://www.optinose.com
Is OptiNose in the S&P 500?
No, OptiNose is not included in the S&P 500 index
Is OptiNose in the NASDAQ 100?
No, OptiNose is not included in the NASDAQ 100 index
Is OptiNose in the Dow Jones?
No, OptiNose is not included in the Dow Jones index
When does OptiNose report earnings?
The next expected earnings date for OptiNose is 09 August 2024